Print Page | Sign In | Join Today
News & Press: Company News

CEL-SCI’s LEAPS rheumatoid arthritis vaccine for accelerator program by NIH

Thursday, September 6, 2018  
Share |
CEL-SCI Corporation announced that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program Phase II awardee for 2018-2019. LEAPS has been specifically selected by the NIH for the Commercialization Transition Track, which provides technical assistance to awardee companies to move NIH-funded technologies towards commercialization and market readiness.

CEL-SCI was eligible and applied for the Commercialization Accelerator Program as part of its $1.5 million Phase II SBIR/STTR NIH grant to develop its LEAPS rheumatoid arthritis vaccine. Only a select number of the SBIR Phase II awarded companies are also accepted into the Commercialization Accelerator Program by the NIH.

“We are pleased that the NIH has selected CEL-SCI and our LEAPS rheumatoid arthritis vaccine candidate for this important commercialization program. We believe the NIH’s program will support and accelerate LEAPS’s advancement into clinical studies and towards commercialization. Preclinical data have shown that LEAPS vaccines may be advantageous to other therapies because LEAPS acts early on the immune system to inhibit the production of disease-promoting inflammatory cytokines,” stated Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected